Anjali K. D. S. Yapa

Anjali K. D. S. Yapa

Auto-generated profile, based on publicly available information

Anjali K. D. S. Yapa

Nottingham Colorectal Service, Nottingham University Hospitals NHS Trust Queen's Medical Centre Nottingham UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
FMFrancesca Ligori Malcolm
Francesca Ligori Malcolm
AYAnjali K. D. S. Yapa
Anjali K. D. S. Yapa
ZWZhen Yu Wong
Zhen Yu Wong
AMAlastair James Morton
Alastair James Morton
CCColin Crooks
Colin Crooks
DHDavid Humes
David Humes
Summary: Background: Faecal haemoglobin (f‐Hb) testing is used in colorectal cancer (CRC) screening and increasingly to guide the investigation in patients with symptoms suggestive of CRC. Studies have demonstrated increased mortality with raised f‐Hb.Aims: To assess the association of raised f‐Hb with all‐cause, non‐CRC (any cause excluding CRC) and cause‐specific mortality.Methods: We searched Medline and Embase on 9 February 2024 to identify papers reporting mortality after faecal immunochemical (FIT) or guaiac faecal occult blood tests (gFOBT). The primary outcome was all‐cause mortality following a positive compared to a negative test.Results: The search identified 3155 papers. Ten met the inclusion criteria: three reported gFOBT and seven reported FIT results, as screening tests. These reported a total of 14,687,625 f‐Hb results. Elevated f‐Hb was associated with an increased risk of all‐cause, non‐CRC and cause‐specific mortality including death from cardiovascular, digestive and respiratory diseases. Crude risk ratios for all‐cause mortality with a positive versus negative test were derived from six papers (three reporting gFOBT, three FIT). An increased risk was demonstrated in five, with RRs ranging from 1.11 (95% CI: 1.06–1.16) to 2.95 (95% CI: 2.85–3.05). For non‐CRC mortality risk, RRs ranged from 1.09 (95% CI: 1.04–1.15) to 2.79 (95% CI: 2.70–2.89). We did not perform meta‐analysis due to a limited number of papers reporting suitable results for each type of f‐Hb test.Conclusions: All‐cause, non‐CRC and cause‐specific mortality appear higher in those with raised f‐Hb. Population‐based studies are warranted to elicit whether this association occurs in symptomatic patients.